144 related articles for article (PubMed ID: 35704436)
1. First-line programmed death receptor-1 (PD-1) inhibitor and epidermal growth factor receptor (EGFR) blockade, combined with platinum-based chemotherapy, for stage IV penile cancer.
Yan R; Ma H; Jiang L; Guo S; Shi Y; Sheng X; Zhang Y; Spiess PE; Liu T; Xue T; Chen X; Li Z; An X; Yao K; Zhou F; Han H
BJU Int; 2023 Feb; 131(2):198-207. PubMed ID: 35704436
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
3. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study.
Necchi A; Lo Vullo S; Perrone F; Raggi D; Giannatempo P; Calareso G; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Togliardi E; Colecchia M; Busico A; Gloghini A; Testi A; Mariani L; Salvioni R
BJU Int; 2018 Mar; 121(3):348-356. PubMed ID: 28921872
[TBL] [Abstract][Full Text] [Related]
4. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant platinum-based chemotherapy and lymphadenectomy for penile cancer: an international, multi-institutional, real-world study.
Rose KM; Pham R; Zacharias NM; Ionescu F; Paravathaneni M; Marchetti KA; Sanchez D; Mustasam A; Sandstrom R; Vikram R; Dhillon J; Rao P; Schneider A; Pagliaro L; Alifrangis C; Albersen M; Roussel E; Master VA; Nazha B; Hernandez C; Moses KA; Protzel C; Montgomery J; Angel M; Tobias-Machado M; Spiess PE; Pettaway CA; Chahoud J
J Natl Cancer Inst; 2024 Jun; 116(6):966-973. PubMed ID: 38366627
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus infection affects treatment outcomes and the immune microenvironment in patients with advanced penile squamous cell carcinoma receiving programmed cell death protein 1 inhibitor-based combination therapy.
Wei L; Li Z; Guo S; Ma H; Shi Y; An X; Huang K; Xiong L; Xue T; Zhang Z; Yao K; Luo J; Han H
Cancer; 2024 May; 130(9):1650-1662. PubMed ID: 38157276
[TBL] [Abstract][Full Text] [Related]
7. Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
Chen C; Zhou Y; Zhang X; Fu S; Lin Z; Fang W; Yang Y; Huang Y; Zhao H; Hong S; Zhang L
Cancer Med; 2020 Mar; 9(5):1721-1732. PubMed ID: 31955525
[TBL] [Abstract][Full Text] [Related]
8. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.
Besse B; Garrido P; Cortot AB; Johnson M; Murakami H; Gazzah A; Gil M; Bennouna J
Lung Cancer; 2020 Apr; 142():63-69. PubMed ID: 32114283
[TBL] [Abstract][Full Text] [Related]
10. Anti-EGFR monoclonal antibody plus chemotherapy for treating advanced non-small cell lung cancer: A meta-analysis.
Luo W; Li Y; Ye F; Li Q; Zhang G; Li J; Li X
Medicine (Baltimore); 2021 Nov; 100(47):e27954. PubMed ID: 34964780
[TBL] [Abstract][Full Text] [Related]
11. Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy.
Pond GR; Di Lorenzo G; Necchi A; Eigl BJ; Kolinsky MP; Chacko RT; Dorff TB; Harshman LC; Milowsky MI; Lee RJ; Galsky MD; Federico P; Bolger G; DeShazo M; Mehta A; Goyal J; Sonpavde G
Urol Oncol; 2014 May; 32(4):501-8. PubMed ID: 24332646
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study.
Mollica V; Massari F; Maruzzo M; Bimbatti D; Claps M; Maiorano BA; Vitale MG; Iacovelli R; Ermacora P; Roviello G; Calabrò F; Caffo O; Vignani F; Grillone F; Pierantoni F; Di Napoli M; Mennitto A; Marchetti A; Mattana A; Cavo A; Bassanelli M; Formisano L; Prati V; Giudice GC; Buti S
Clin Genitourin Cancer; 2024 Jun; 22(3):102074. PubMed ID: 38616147
[TBL] [Abstract][Full Text] [Related]
13. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of PD-1 inhibitors plus chemotherapy with or without endostatin for stage IV lung squamous cancer: a retrospective study.
Lv C; Wu Y; Gu W; Du B; Yao N; Zhu Y; Zheng J; Hong Y; Lai J
Front Immunol; 2024; 15():1413204. PubMed ID: 38911862
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma.
Riudavets M; Bosch-Barrera J; Cabezón-Gutiérrez L; Diz Taín P; Hernández A; Alonso M; Blanco R; Gálvez E; Insa A; Mielgo X; Morán T; Ponce S; Roa D; Sánchez JM; Majem M
Clin Transl Oncol; 2021 Dec; 23(12):2560-2567. PubMed ID: 34292495
[TBL] [Abstract][Full Text] [Related]
16. Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE.
Gassian N; Frontczak A; Mouillet G; Vernerey D; Manseur O; Goujon M; Meurisse A; Berthod D; Robert E; Calcagno F; Thiery-Vuillemin A
Bull Cancer; 2020 Jun; 107(5S):eS16-eS21. PubMed ID: 32620211
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis.
Carthon BC; Ng CS; Pettaway CA; Pagliaro LC
BJU Int; 2014 Jun; 113(6):871-7. PubMed ID: 24053151
[TBL] [Abstract][Full Text] [Related]
18. Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study.
García Del Muro X; Páez López-Bravo D; Cuéllar-Rivas MA; Maroto P; Giannatempo P; Castellano D; Climent MA; P Valderrama B; Gómez de Liaño A; López-Montero L; Mina L; Alcalá-López D; Sampayo-Cordero M; Necchi A
Eur Urol Oncol; 2024 May; ():. PubMed ID: 38749903
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.
Ali SM; Pal SK; Wang K; Palma NA; Sanford E; Bailey M; He J; Elvin JA; Chmielecki J; Squillace R; Dow E; Morosini D; Buell J; Yelensky R; Lipson D; Frampton GM; Howley P; Ross JS; Stephens PJ; Miller VA
Oncologist; 2016 Jan; 21(1):33-9. PubMed ID: 26670666
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab for the better treatment of EGFR-mutant T790M-negative advanced lung adenocarcinoma patients than dual treatment of pemetrexed plus platinum after tyrosine kinase inhibitor treatment failure.
Lu Z; Ye M; Sun T; Wu S; Lin Z; Zhang X; Rao D; Zhang D; Ke Y; Chen Z
Ann Palliat Med; 2022 Jun; 11(6):2100-2109. PubMed ID: 35817745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
